Response and tolerability of a single dose of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: A multicenter retrospective analysis

Journal of Nuclear Medicine

Volumn 57, Issue 9, 2016, Pages 1334-1338

  Rahbar, Kambiz ^a   Schmidt, Matthias ^b   Heinzel, Alexander ^c   Eppard, Elisabeth ^d   Bode, Axel ^a   Yordanova, Anna ^d   Claesener, Michael ^a   Ahmadzadehfar, Hojjat ^d  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^d UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

177Lu PSMA; MCRPC; Prostate cancer; Radioligand therapy

Indexed keywords

ABIRATERONE; ALKALINE PHOSPHATASE; CABAZITAXEL; CREATININE; DOCETAXEL; ENZALUTAMIDE; HEMOGLOBIN; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN 617 LU 177; RADIOPHARMACEUTICAL AGENT; RADIUM CHLORIDE RA 223; UNCLASSIFIED DRUG; 177LU-PSMA-617; DIPEPTIDE; SINGLE HETEROCYCLIC RINGS;

ADULT; AGED; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER GROWTH; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; COHORT ANALYSIS; COMPASSIONATE USE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHROCYTE TRANSFUSION; FOLLOW UP; HEMATOLOGICAL PARAMETERS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; KIDNEY SCINTISCANNING; LEUKOCYTE COUNT; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATECTOMY; QUALITY OF LIFE; REFERENCE VALUE; RETROSPECTIVE STUDY; SALVAGE THERAPY; SINGLE DRUG DOSE; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT REFUSAL; WHOLE BODY SCINTISCANNING; XEROSTOMIA; CLINICAL TRIAL; DOSE RESPONSE; LYMPHATIC METASTASIS; MIDDLE AGED; MULTICENTER STUDY; PROSTATIC NEOPLASMS; RADIATION INJURIES; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; DIPEPTIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84989287555     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.116.173757     Document Type: Article

References (17)

1. Afshar-Oromieh A, Malcher A, Eder M, et al. PET imaging with a [68Ga]galliumlabelled PSMA ligand for the diagnosis of prostate cancer: Biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486-495.
2. Eiber M, Maurer T, Souvatzoglou M, et al. Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56:668-674.
3. Afshar-Oromieh A, Avtzi E, Giesel FL, et al. The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197-209.
4. Rowe SP, Gage KL, Faraj SF, et al. 18F-DCFBC PET/CT for PSMA-based detection and characterization of primary prostate cancer. J Nucl Med. 2015;56:1003-1010.
5. Rahbar K, Weckesser M, Huss S, et al. Correlation of intraprostatic tumor extent with 68Ga-PSMA distribution in patients with prostate cancer. J Nucl Med. 2016;57:563-567.
6. Deb N, Goris M, Trisler K, et al. Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody. Clin Cancer Res. 1996;2:1289-1297.
7. Tagawa ST, Milowsky MI, Morris M, et al. Phase II study of lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013;19:5182-5191.
8. Ahmadzadehfar H, Rahbar K, Kurpig S, et al. Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: A two-centre study. EJNMMI Res. 2015;5:114.
9. Afshar-Oromieh A, Hetzheim H, Kratochwil C, et al. The novel theranostic PSMA-ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: Biodistribution in humans, radiation dosimetry and first evaluation of tumor lesions. J Nucl Med. 2015;56:1697-1705.
10. Bubeck B, Brandau W, Weber E, Pomer S, Georgi P, zum Winkel K. Renal function studies using 99mTc-MAG3: pharmacokinetics and slope clearance determination. Contrib Nephrol. 1990;79:72-73.
11. Zajic T, Moser E. Procedure guidelines for dynamic renal scintigraphy. Nuklearmedizin. 2004;43:177-180.
12. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group. J Clin Oncol. 2008;26:1148-1159.
13. BǍrinka C, Rojas C, Slusher B, Pomper M. Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer. Curr Med Chem. 2012;19:856-870.
14. Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol. 2005;23:4591-4601.
15. Zechmann CM, Afshar-Oromieh A, Armor T, et al. Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging. 2014;41: 1280-1292.
16. Baum RP, Kulkarni HR, Schuchardt C, et al. Lutetium-177 PSMA radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy. J Nucl Med. January 21, 2016.
17. Delker A, Fendler WP, Kratochwil C, et al. Dosimetry for 177Lu-DKFZ-PSMA- 617: A new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:42-51.